NewcelX (NCEL) Shares Outstanding (2019 - 2025)
NewcelX (NCEL) posted quarterly Shares Outstanding (Entity) of $5.4 million for Q4 2025, up 2390.79% year-over-year from $218595.0 in Q4 2024, and up 859.83% quarter-over-quarter from $567262.0 in Q2 2025.
NewcelX (NCEL) Shares Outstanding (2019 - 2025) Analysis & Trends
NewcelX (NCEL) has reported Shares Outstanding (Entity) for 7 consecutive years, with $5.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Shares Outstanding (Entity) rose 2390.79% year-over-year to $5.4 million; the TTM figure through Dec 2025 stood at $5.4 million (up 2390.79% YoY), while the FY2025 annual figure was $5.4 million, up 2390.79% from the prior year.
- Shares Outstanding (Entity) advanced to $5.4 million in Q4 2025 per NCEL's latest filing, from $567262.0 in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $5.4 million in Q4 2025 and bottomed at $18449.0 in Q2 2021.
- Historically, Shares Outstanding (Entity) has averaged $667551.3 across 5 years, with a median of $99405.5 in 2023.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) jumped 43.57% — and 2025, when it surged 2390.79%.
- NewcelX's Shares Outstanding (Entity) stood at $19836.0 in 2021, then surged by 65.38% to $32805.0 in 2022, then soared by 312.08% to $135184.0 in 2023, then jumped by 61.7% to $218595.0 in 2024, then soared by 2390.79% to $5.4 million in 2025.
- Business Quant data shows NCEL's Shares Outstanding (Entity) at $5.4 million in Q4 2025, $567262.0 in Q2 2025, and $218595.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | NewcelX | 12.54 Mn | 10.34 Mn | - | 3.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.84 Mn |
| Jun 30, 2025 | 400,487.00 |
| Dec 31, 2024 | 154,328.00 |
| Jun 30, 2024 | 104,863.00 |
| Dec 31, 2023 | 95,440.00 |
| Jun 30, 2023 | 95,440.00 |
| Dec 31, 2022 | 49,207.00 |
| Jun 30, 2022 | 39,731.00 |
| Dec 31, 2021 | 29,754.00 |
| Jun 30, 2021 | 27,673.00 |
| Dec 31, 2020 | 17,400.00 |
| Dec 31, 2019 | 17,100.00 |